Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn unspecified lectican proteoglycans (nourkrin)
learn Lupine protein
Research
5 / 1000+ resultsresearch Signature selection analysis reveals candidate genes associated with production traits in Iranian sheep breeds
Certain genes in Iranian sheep are linked to wool production and heat adaptation.
research Cold atmospheric microwave plasma (CAMP) stimulates dermal papilla cell proliferation by inducing β-catenin signaling
Cold Atmospheric Microwave Plasma (CAMP) helps hair cells grow and could potentially treat hair loss.
research 0749 Serine and arginine-rich splicing factor 3 regulates epidermal differentiation in cutaneous squamous cell carcinoma
research Nanoporous Silica Entrapped Lipid-Drug Complexes for the Solubilization and Absorption Enhancement of Poorly Soluble Drugs
Nanoporous silica entrapped lipid-drug complexes significantly improve the solubility and absorption of drugs that don't dissolve well in water.
research Dental cell type atlas reveals stem and differentiated cell types in mouse and human teeth
The research identified various cell types in mouse and human teeth, which could help in developing dental regenerative treatments.
Community Join
5 / 1000+ resultscommunity Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community RU55481
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.